We have located links that may give you full text access.
Targetability of osteoid osteomas and bone metastases by MR-guided high intensity focused ultrasound (MRgHIFU).
International Journal of Hyperthermia 2018 September 14
PURPOSE: To retrospectively evaluate the suitability of MRgHIFU for osteoid osteomas (OOs) and bone metastases in patients who underwent minimally-invasive percutaneous thermal ablation.
MATERIALS AND METHODS: One hundred and sixty-seven lesions (115 metastases and 52 OOs) treated percutaneously between October 2014 and June 2017 were retrospectively analyzed. Tumors were located in the spine or sacrum (54), pelvis (43), limbs (50), ribs (17) and sternum (3). Tumor volume, matrix, anatomical environment and need for protection of surrounding structures or consolidation were assessed. Cases were classified into three categories: (a) lesions suitable for MRgHIFU therapy alone; (b) lesions suitable for MRgHIFU if protection of surrounding structures and/or bone consolidation is performed; (c) lesions not suitable for MRgHIFU.
RESULTS: Twenty-six (50%) of OOs were classified as suitable for MRgHIFU alone and 17 (32.7%) as suitable for MRgHIFU with hydro-dissection. Matrix of treatable OOs was sclerotic (19), lytic (15) or mixed (9), with mean volume 0.56 cm3 . Forty-one (35.7%) of metastases were classified as suitable for MRgHIFU alone and 43 (37.4%) as suitable with hydro-dissection and/or consolidation. Matrix of metastases was sclerotic (13), lytic (37) or mixed (34), with mean volume 71.9 cm3 . Mean depth of targetable lesions was 50.9 ± 28.4 mm. 97.7% of pelvic lesions and 94% of peripheral bone lesions were targetable by HIFU. 66.6% of spinal or sacral lesions were considered untreatable.
CONCLUSION: MRgHIFU cannot be systematically performed non-invasively on bone tumors. Combination with minimally-invasive thermo-protective techniques may increase the number of eligible cases.
MATERIALS AND METHODS: One hundred and sixty-seven lesions (115 metastases and 52 OOs) treated percutaneously between October 2014 and June 2017 were retrospectively analyzed. Tumors were located in the spine or sacrum (54), pelvis (43), limbs (50), ribs (17) and sternum (3). Tumor volume, matrix, anatomical environment and need for protection of surrounding structures or consolidation were assessed. Cases were classified into three categories: (a) lesions suitable for MRgHIFU therapy alone; (b) lesions suitable for MRgHIFU if protection of surrounding structures and/or bone consolidation is performed; (c) lesions not suitable for MRgHIFU.
RESULTS: Twenty-six (50%) of OOs were classified as suitable for MRgHIFU alone and 17 (32.7%) as suitable for MRgHIFU with hydro-dissection. Matrix of treatable OOs was sclerotic (19), lytic (15) or mixed (9), with mean volume 0.56 cm3 . Forty-one (35.7%) of metastases were classified as suitable for MRgHIFU alone and 43 (37.4%) as suitable with hydro-dissection and/or consolidation. Matrix of metastases was sclerotic (13), lytic (37) or mixed (34), with mean volume 71.9 cm3 . Mean depth of targetable lesions was 50.9 ± 28.4 mm. 97.7% of pelvic lesions and 94% of peripheral bone lesions were targetable by HIFU. 66.6% of spinal or sacral lesions were considered untreatable.
CONCLUSION: MRgHIFU cannot be systematically performed non-invasively on bone tumors. Combination with minimally-invasive thermo-protective techniques may increase the number of eligible cases.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app